Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Garrett M Brodeur

Showing results (41-50 of 88) with videos related to

Pageof 9
Sort By:
Journal of Cancer Research and Clinical Oncology|October 5, 2019
The effectiveness of Wilms tumor screening in Beckwith-Wiedemann spectrumAlessandro Mussa, Kelly A Duffy, Diana Carli, et al.
International Journal of Molecular Sciences|February 15, 2022
Nanocarrier-Based Delivery of SN22 as a Tocopheryl Oxamate Prodrug Achieves Rapid Tumor Regression and Extends Survival in High-Risk Neuroblastoma ModelsIvan S Alferiev, David T Guerrero, Danielle Soberman, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 22, 2022
Poloxamer-linked prodrug of a topoisomerase I inhibitor SN22 shows efficacy in models of high-risk neuroblastoma with primary and acquired chemoresistanceIvan S Alferiev, David T Guerrero, Peng Guan, et al.
Cancer|December 29, 2015
Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group projectDaria Thompson, Kieuhoa T Vo, Wendy B London, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2009
Trk receptor expression and inhibition in neuroblastomasGarrett M Brodeur, Jane E Minturn, Ruth Ho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2017
Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition SyndromeWilliam D Foulkes, Junne Kamihara, D Gareth R Evans, et al.
Pediatric Blood & Cancer|May 23, 2019
Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) projectKevin Campbell, Derek Shyr, Rochelle Bagatell, et al.
Hormone Research in Paediatrics|April 22, 2021
The Clinical Spectrum of PTEN Hamartoma Tumor Syndrome: Exploring the Value of Thyroid SurveillanceJulia A Baran, Steven D Tsai, Amber Isaza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2005
Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group studyRani E George, Wendy B London, Susan L Cohn, et al.
JCO Precision Oncology|August 13, 2020
Pediatric Somatic Tumor Sequencing Identifies Underlying Cancer PredispositionSuzanne P MacFarland, Kristin Zelley, Lea F Surrey, et al.
Pageof 9

Showing results (41-50 of 88) with videos related to

Sort By:
Pageof 9
Journal of Cancer Research and Clinical Oncology|October 5, 2019
The effectiveness of Wilms tumor screening in Beckwith-Wiedemann spectrumAlessandro Mussa, Kelly A Duffy, Diana Carli, et al.
International Journal of Molecular Sciences|February 15, 2022
Nanocarrier-Based Delivery of SN22 as a Tocopheryl Oxamate Prodrug Achieves Rapid Tumor Regression and Extends Survival in High-Risk Neuroblastoma ModelsIvan S Alferiev, David T Guerrero, Danielle Soberman, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 22, 2022
Poloxamer-linked prodrug of a topoisomerase I inhibitor SN22 shows efficacy in models of high-risk neuroblastoma with primary and acquired chemoresistanceIvan S Alferiev, David T Guerrero, Peng Guan, et al.
Cancer|December 29, 2015
Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group projectDaria Thompson, Kieuhoa T Vo, Wendy B London, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2009
Trk receptor expression and inhibition in neuroblastomasGarrett M Brodeur, Jane E Minturn, Ruth Ho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2017
Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition SyndromeWilliam D Foulkes, Junne Kamihara, D Gareth R Evans, et al.
Pediatric Blood & Cancer|May 23, 2019
Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) projectKevin Campbell, Derek Shyr, Rochelle Bagatell, et al.
Hormone Research in Paediatrics|April 22, 2021
The Clinical Spectrum of PTEN Hamartoma Tumor Syndrome: Exploring the Value of Thyroid SurveillanceJulia A Baran, Steven D Tsai, Amber Isaza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2005
Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group studyRani E George, Wendy B London, Susan L Cohn, et al.
JCO Precision Oncology|August 13, 2020
Pediatric Somatic Tumor Sequencing Identifies Underlying Cancer PredispositionSuzanne P MacFarland, Kristin Zelley, Lea F Surrey, et al.
Pageof 9